Skip to main content
. Author manuscript; available in PMC: 2018 Nov 1.
Published in final edited form as: Neuropharmacology. 2017 Sep 9;126:224–232. doi: 10.1016/j.neuropharm.2017.09.013

Figure 5. 5-HT2 receptor antagonists have no effect on 5-HT inhibition of EPSCs in cortical pathway.

Figure 5

In the presence of 5-HT2A antagonist MDL 100907 (10 µM) (A) or non-selective 5-HT2 antagonist pirenperone (10 µM)(B), 5-HT (10 µM) significantly decreased the amplitude of cortical eEPSCs, which is not different from 5-HT effect in control ACSF (C).